Mobile

A randomized, double-blind phase II trial to assess the efficacy and safety of bicalutamide (Casodex® ) associated to ZD6474 (Zactima™ ) or to placebo in patients with castration-refractory metastatic...

Update Il y a 4 ans
Reference: EUCTR2007-001891-35

A randomized, double-blind phase II trial to assess the efficacy and safety of bicalutamide (Casodex® ) associated to ZD6474 (Zactima™ ) or to placebo in patients with castration-refractory metastatic prostate cancer without any clinical symptom related to disease progression

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To assess the effect of ZD6474 (Vandetanib, Zactima™ ) on time to prostate specific antigen (PSA) progression (TTP) in patients with castration-refractory metastatic prostate cancer, without any clinical symptom related to disease progression.

Inclusion criteria

  • metastatic prostate cancer

Links